A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N

• Main Authors: Fredrik Sundquist (Author), Kleopatra Georgantzi (Author), Kirsten Brunsvig Jarvis (Author), Jesper Brok (Author), Minna Koskenvuo (Author), Jelena Rascon (Author), Max van Noesel (Author), Per Grybäck (Author), Joachim Nilsson (Author), Arthur Braat (Author), Mikael Sundin (Author), Sandra Wessman (Author), Nikolas Herold (Author), Lars Hjorth (Author), Per Kogner (Author), Dan Granberg (Author), Mark Gaze (Author), Jakob Stenman (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundHalf the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor. 131I-mIBG is the most widely used form in current use, but is not universally effective. Clinical trials of 17...